Pete V. Domenici, United States Senate, Washington, D.C.

* Patricia Goldman-Rakic, Department of Neuroscience, Yale University School of Medicine, New Haven, Connecticut

Murray Goldstein, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, Maryland

Frederick K. Goodwin, Alcohol, Drug Abuse, and Mental Health Administration, Rockville, Maryland

Enoch Gordis, National Institute on Alcohol Abuse and Alcoholism, Alcohol, Drug Abuse, and Mental Health Administration, Rockville, Maryland

Alberto Grignolo, FIDIA Pharmaceuticals, Washington, D.C.

Roger Guillemin, Whittier Institute, La Jolla, California

David H. Hubel, Department of Neurobiology, Harvard University Medical School, Boston, Massachusetts

Lily Yeh Jan, Department of Physiology, University of California, San Francisco

Richard T. Johnson, Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland

Lewis L. Judd, National Institute of Mental Health, Alcohol, Drug Abuse, and Mental Health Administration, Rockville, Maryland

Eric R. Kandel, Center for Neurobiology and Behavior, Columbia University, New York, New York

Carl Kupfer, National Eye Institute, National Institutes of Health, Bethesda, Maryland

Thomas W. Langfitt, The Glenmede Trust Company and The Pew Charitable Trusts, Philadelphia, Pennsylvania

Robert Lefkowitz, Duke University Medical Center, Durham, North Carolina

Alan I. Leshner, National Institute of Mental Health, Alcohol, Drug Abuse, and Mental Health Administration, Rockville, Maryland